Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

COVID: antiviral drugs are a vital weapon – but misusing them could backfire

The “living with COVID” strategy being pursued by many countries relies heavily on two key pillars. First, that vaccines continue to protect most people from severe disease. And second, that where they don’t, people will receive antiviral treatments. But are the antivirals currently available sufficiently effective, accessible and durable?

The Conversation

Lisa Jarvis: At last, a simple strategy for COVID booster shots

The Food and Drug Administration reportedly has a new strategy for rolling out new booster shots that should bring needed clarity to COVID vaccination in the U.S. Going forward, most Americans will get the same advice about when to get their next shots.

Tribune News Service

How common is Paxlovid rebound as Biden tests positive again for Covid?

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

The kids are all right: Fewer COVID-19 vaccine side effects

Australian children aged 5–15 years have reported fewer side effects in the days after receiving the mRNA COVID-19 vaccine than those in clinical trials.

The New Daily

Biden tests positive for COVID-19 again, returns to isolation

White House physician Dr. Kevin O’Connor said in a letter that Biden “has experienced no reemergence of symptoms, and continues to feel quite well.”

Chicago Sun-Times

Andrew Hopkins of Exscientia: the man using AI to cure disease

The British scientist’s company employs artificial intelligence to drastically cut the time of drug development

The Guardian - UK

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review

The stock market rally made big moves amid a barrage of earnings and economic reports and another big Fed rate hike.

Investors Business Daily

Pfizer Tumbles On Lackluster Outlook Despite A Covid-Driven Quarterly Beat

Pfizer stock tumbled Thursday after delivering a second-quarter beat almost entirely on the back of its Covid vaccine and antiviral pill.

Investors Business Daily

Dow Jones Rises As GDP Signals Recession; Meta Slides On Earnings; Apple Earnings Due

The Dow Jones Industrial Average rose Thursday, as tech giant Meta Platforms slid on weak earnings results. Apple earnings are due next.

Investors Business Daily

Zenara Pharma gets CDSCO nod to make copy of Pfizer’s Paxlovid

Combi pack of Nirmatrelvir, Ritonavir tablets is for patients with moderate symptoms of Covid-19

The Hindu

Pfizer Stock Turns Higher After Covid Sales Power Q2 Earnings Beat, Profit Guidance Boost

Pfizer held to its forecast of $54 billion in Covid related sales this year following stronger-than-expected second quarter earnings and record overall revenues.

The Street

Dow Jones Futures Fall On 'Day 2' After Market Rallies Strongly On Powell Hints Of Slower Fed Rate Hikes

Stocks rallied strongly Wednesday after Fed chief Jerome Powell hinted at slower Fed rate hikes. Watch out for day 2 reactions

Investors Business Daily

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bearish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

What is Paxlovid? Everything you need to know about Joe Biden’s antiviral Covid drug treatment

Late-stage clinical trial found nearly 90 per cent effectiveness from antiviral pill

Los Angeles Times

Should you wait for the omicron booster? Why experts say you should 'get it now!'

If you're like most Americans, you've gotten your primary doses of a COVID-19 vaccine, but you haven't gotten the recommended booster shots. So if it's been several months since your last primary dose, you're probably due for a booster.

Investors Business Daily

Huge Returns Available On Pfizer Stock For High-Risk Option Traders

Some traders prefer trading short-term options which have the potential to generate much higher gains on an annualized basis.

StockNews.com

3 High-Quality Stocks to Pick Up for the Second-Half

The bear market provides an opportunity for investors to buy shares of high-quality companies at attractive valuations. Below are 3 such stocks that investors should consider buying during this market correction: Elevance Health (ELVH), Pfizer (PFE), and Builders FirstSource (BLDR).

Get all your
news in one place.

100’s of premium titles.
One news app.

The Canberra Times

High number of COVID-19 hospitalisations in ACT but only one in ICU

The ACT recorded 949 new COVID-19 cases in the 24 hours until 8pm Monday.

Irish Mirror

Man goes from council estate to €470m fortune with artificial intelligence

Andrew Hopkins grew up on a council estate but described how he has since swapped that life for one in the prestigious city of Oxford after setting up his company, Exscientia

360info

Poor-quality medicines are everyone’s problem

COVID-19 has shown that regulatory processes can fail anywhere, allowing poor-quality medicines through. A new detection test could help shield consumers.

Wales Online

The man from a Welsh council estate now worth £400m thanks to an idea he had on his walk home

Andrew Hopkins has developed a biotech company called Exscientia which is revolutionising the industry

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The New Daily

COVID-19 antivirals: Millions are now eligible, but the drugs are no substitute for boosters

Millions of Australians are now eligible for using antivirals to prevent serious illness or death from COVID-19. But it's complicated.

Los Angeles Times

Why Biden’s bout with COVID-19 is likely to be easier than Trump’s

Nearly two years separate the COVID-19 diagnoses of then-President Donald Trump and current President Joe Biden. In a pandemic that has engaged the full powers of the American medical and scientific establishments, that is a lifetime.

1 … 39 40 41 42

People

Andrés Manuel López Obrador

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations